Neoplastic transformation of germinal center B (GCB) cells may give rise to a variety of different B cell lymphoma subtypes, most of which show substantial heterogeneity in terms of genetic alterations and clinical features. The mutations observed in cancer related genes in GCB cells are related to abnormalities in the immunogenetic mechanisms associated with germinal center reaction. Recent studies have rapidly identified genomic alterations in B cell lymphomas that may be useful for better subclassification, noninvasive diagnosis, and prediction of response to therapy. The WHO recognizes different lymphoma subsets classified within 2 major categories of B cell lymphoma: Hodgkin's lymnphomna (HL) and B cell non-Hodgkin's lymnphomna (NHL), each with distinct genetic aberrations, including chromosomal translocations, copy number abnormalities, or point mutations. Next-generation sequencing-based technologies have allowed cancer researchers to identify somatic mutations and gene expression signatures at a rapid pace so that novel diagnostic or prognostic biomarkers, as well as therapeutic targets, can be discovered much faster than before. Indeed, deep sequencing studies have recently revealed that lymphoma-specific somatic mutations may be detected in cell-free circulating DNA obtained from the peripheral blood of B cell lymphoma patients, suggesting the possibility of minimally invasive diagnosis, monitoring, and predicting response to therapy of B cell lymphoma patients. In this study, the current status of the recurrent genetic aberrations observed during diagnosis and/ or relapse in HL and the major subtypes of B cell NHL (i.e. diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymnphomna) are discussed to shed light on their potential use as noninvasive diagnostic or prognostic biomarkers and to reveal their role in lymphomagenesis as a target in therapy for newly diagnosed and chemotherapy-resistant cases.
Purpose: The global pandemic COVID-19, caused by the coronavirus SARS-CoV-2, is persistent despite the increasing vaccination rates, with new cases being reported per week. MicroRNAs, that is, non-coding RNA species that regulate gene expression at the post-transcriptional level, play a pivotal role in the SARS-CoV-2 life cycle, pathophysiology and host’s anticoronaviral responses. The objective of this study was the in silico discovery of functionally associated miRNAs that likely co-regulate COVID-19-related genes Materials and Methods: In the present study, an integrative bioinformatics approach was employed, including database searching, gene set enrichment analysis, network-based and microRNA target prediction methods, towards the discovery of epigenetic determinants of COVID-19. Results: An intricate microRNA-target gene network was constructed, and a set of 8 highly interacting microRNAs, that potentially co-target and co-regulate key COVID-19-related genes, was detected. These miRNAs and their corresponding genes are likely involved in the host’s response to SARS-CoV-2 infection. Conclusion: The 8 functionally associated miRNAs could constitute a signature for COVID-19 diagnosis.